Quick Answer
X4 Pharmaceuticals, Inc reported Diluted EPS of $1.87 per share (loss) for fiscal year 2025.
X4 Pharmaceuticals, Inc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.87 | +66.5% |
| 2024 | -$5.59 | +67.3% |
| 2023 | -$17.07 | -1023.0% |
| 2022 | -$1.52 | +61.9% |
| 2021 | -$3.99 | -29.1% |
| 2020 | -$3.09 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.69 | +87.4% | +80.1% |
| June 30, 2025 | -$3.47 | -125.6% | -8775.0% |
| March 31, 2025 | $0.04 | +100.5% | +100.7% |
| September 30, 2024 | -$5.48 | -54700.0% | -140.4% |
| June 30, 2024 | $13.57 | +4212.1% | +274.6% |
| March 31, 2024 | -$7.77 | -4756.2% | -77600.0% |
| September 30, 2023 | -$0.01 | +96.2% | +97.0% |
| June 30, 2023 | -$0.33 | +45.0% | -106.2% |
- X4 Pharmaceuticals, Inc showed an increase of +66.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, X4 Pharmaceuticals, Inc’s diluted eps has grown by 39.5% (from $3.09 per share (loss) to $1.87 per share (loss)).
- The most recent figure is from X4 Pharmaceuticals, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: